KMB Stock Analysis: Kimberly-Clark | NASDAQ
Household & Personal Products | NASDAQ, USA | Market Cap: 32.752m USD | 12M Return: -20.3% | US4943681035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 349M
EPS Trend: 84.9%
Qual. Beats: -1
Rev. Trend: -97.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kimberly-Clark Corporation manufactures and markets personal care products primarily in the United States, operating through two segments: North America and International Personal Care. Its product portfolio spans baby and child care (including disposable diapers, training pants, swimpants, and wipes), feminine and incontinence care, facial and bathroom tissue, paper towels, napkins, and wipers. The company sells well-known consumer brands such as Huggies, Pull-Ups, Kotex, Depend, Kleenex, Scott, Cottonelle, Viva, and WypAll, distributing household products through supermarkets, mass merchandisers, drugstores, warehouse clubs, and e-commerce channels. It also serves a professional/B2B market, supplying manufacturing, lodging, office, food service, and high-volume public facilities through distributors and direct sales. The company was founded in 1872 and is headquartered in Dallas, Texas.
As a large-cap consumer staples company in the household products sub-industry, Kimberly-Clark operates in a defensive sector characterized by relatively stable, recurring demand for essential personal care and hygiene goods. Its business model relies on a portfolio of legacy brands with strong household recognition, supported by dual distribution into both retail consumer channels and the away-from-home professional segment.
- Pulp and resin input costs pressure personal care margins
- International segment revenue pressured by emerging market FX volatility
- North America private label competition limits pricing power
| Net Income: 1.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: -3.83% < 20% (prev -8.93%; Δ 5.10% < -1%) |
| CFO/TA 0.18 > 3% & CFO 3.33b > Net Income 1.96b |
| Net Debt (5.69b) to EBITDA (3.05b): 1.86 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (333.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 36.69% > 18% (prev 35.56%; Δ 1.13% > 0.5%) |
| Asset Turnover: 93.79% > 50% (prev 107.8%; Δ -13.99% > 0%) |
| Interest Coverage Ratio: 10.44 > 6 (EBIT TTM 2.46b / Interest Expense TTM 236.0m) |
| A: -0.03 (Total Current Assets 6.35b - Total Current Liabilities 6.99b) / Total Assets 18.6b |
| B: 0.53 (Retained Earnings 9.77b / Total Assets 18.6b) |
| C: 0.14 (EBIT TTM 2.46b / Avg Total Assets 17.7b) |
| D: 0.11 (Book Value of Equity 1.75b / Total Liabilities 16.7b) |
| Altman-Z'' = 2.54 = A |
| DSRI: 1.01 (Receivables 1.86b/2.01b, Revenue 16.6b/18.1b) |
| GMI: 0.97 (GM 35.56% / 36.69%) |
| AQI: 0.97 (AQ_t 0.28 / AQ_t-1 0.29) |
| SGI: 0.92 (Revenue 16.6b / 18.1b) |
| TATA: -0.07 (NI 1.96b - CFO 3.33b) / TA 18.6b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of September 14, 2026, the stock is trading at USD 98.15 with a total of 8,136,406 shares traded. Over the past week, the price has changed by -7.99%, over one month by -8.51%, over three months by -2.18% and over the past year by -20.31%.
Current recommended Stop Loss: 92.90 (which is 5.3% or 2.1 ATR below the current price).
Kimberly-Clark has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold KMB.
- StrongBuy: 3
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 118.6 | 20.8% |
P/E Trailing = 19.501
P/E Forward = 13.1062
P/S = 1.9752
P/B = 18.7575
P/EG = 1.986
Revenue TTM = 16.6b USD
EBIT TTM = 2.46b USD
EBITDA TTM = 3.05b USD
Long Term Debt = 6.47b USD (from longTermDebt, last quarter)
Short Term Debt = 43.0m USD (from shortTermDebt, last quarter)
Debt = 6.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 128.0m
Net Debt = 5.69b USD (calculated: Debt 6.64b - CCE 956.0m)
Enterprise Value = 38.4b USD (32.8b + Debt 6.64b - CCE 956.0m)
Interest Coverage Ratio = 10.44 (Ebit TTM 2.46b / Interest Expense TTM 236.0m)
EV/FCF = 15.01x (Enterprise Value 38.4b / FCF TTM 2.56b)
FCF Yield = 6.66% (FCF TTM 2.56b / Enterprise Value 38.4b)
FCF Margin = 15.46% (FCF TTM 2.56b / Revenue TTM 16.6b)
Net Margin = 11.80% (Net Income TTM 1.96b / Revenue TTM 16.6b)
Gross Margin = 36.69% ((Revenue TTM 16.6b - Cost of Revenue TTM 10.5b) / Revenue TTM)
Gross Margin QoQ = 38.27% (prev 36.85%)
Tobins Q-Ratio = 2.07 (Enterprise Value 38.4b / Total Assets 18.6b)
Interest Expense / Debt = 3.55% (Interest Expense 236.0m / Debt 6.64b)
Taxrate = 29.50% (674.0m / 2.29b)
NOPAT = 1.74b (EBIT 2.46b * (1 - 29.50%))
Current Ratio = 0.91 (Total Current Assets 6.35b / Total Current Liabilities 6.99b)
Debt / Equity = 3.80 (Debt 6.64b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 1.86 (Net Debt 5.69b / EBITDA 3.05b)
Debt / FCF = 2.22 (Net Debt 5.69b / FCF TTM 2.56b)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.07% (Net Income 1.96b / Total Assets 18.6b)
RoE = 122.6% (Net Income TTM 1.96b / Total Stockholder Equity 1.59b)
RoCE = 30.52% (EBIT 2.46b / Capital Employed (Equity 1.59b + L.T.Debt 6.47b))
RoIC = 16.11% (NOPAT 1.74b / Invested Capital 10.8b)
WACC = 5.17% (E(32.8b)/V(39.4b) * Re(5.71%) + D(6.64b)/V(39.4b) * Rd(3.55%) * (1-Tc(0.29)))
Discount Rate = 5.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.14 | Cagr: -0.66%
[DCF] Terminal Value 77.97% ; FCFF base≈2.38b ; Y1≈2.73b ; Y5≈4.01b
[DCF] Fair Price = 164.4 (EV 60.4b - Net Debt 5.69b = Equity 54.7b / Shares 332.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.89 | EPS CAGR: 4.45% | SUE: -1.98 | # QB: -1
Revenue Correlation: -97.37 | Revenue CAGR: -7.86% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.67 | Chg30d=+1.41% | Revisions=-67% | Analysts=14
EPS current Year (2026-12-31): EPS=7.45 | Chg30d=+0.60% | Revisions=-72% | GrowthEPS=-1.1% | GrowthRev=+1.2%
EPS next Year (2027-12-31): EPS=7.50 | Chg30d=-0.48% | Revisions=-50% | GrowthEPS=+0.7% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: -73% (up=4, down=34)